PPT-Use of Injectable CAB/RPV LA as Replacement ART in

Virally Suppressed Adults wwwhivguidelinesorg MAY 2023 NYSDOH AIDS Institute Clinical Guidelines Program Purpose of This Guideline Weigh the risks and benefits of switching from an oral to an injectable ART regimen. Restructure Plan. RC Formations generally cost 1/3 of what the AC costs. This plan has 2 ARNG . Bdes. per AC . Bde. or a 1/3 – 2/3 ratio . National Guard. Aviation Proposal. Reduce number of Combat Aviation Brigades from 21 to 18 (6 AC to 12 ARNG) as opposed to the AC plan to cut from 21 to 10 – . 38 UH-60, 15 HH-60, 12 CH-47 . 45 . AH-64, 12 RQ-7, 12 . MQ-1C. CAB (Full-Spectrum) (. x8). . ARNG CAB. 38 UH-60, 15 HH-60, 12 CH-47 . 21 . AH-64, . 24 . RQ-7, . 24 MQ-1C. CAB (Full-Spectrum) (. x10). Switch to DTG + RPV. SWORD. . Study. Switch to CAB LA + RPV LA IM. LATTE-2 Study. . . LATTE-2 Study: switch to cabotegravir LA + rilpivirine LA IM. Objective. Primary: % HIV RNA < 50 c/mL at W32 of maintenance phase: selection of dosing schedule for phase III studies (confirmation of dose on W48 analysis) ; safety. Nyaradzo M Mgodi (. MBChB. , . MMed. ). On behalf of the HPTN-076 Team. UZ-UCSF Annual Research Day. May 05, 2017 Harare. Background. Introduction to . Rilpivirine. (TMC 278). HPTN-076. Study Design. Rebecca McDonald. National Addiction . Centre. King’s College London. Declarations. RM has undertaken an unpaid student industry placement with . Mundipharma. Research Ltd., with focus on the analysis of naloxone nasal spray formulations. New Drugs in Development Are We Ready for Long-Acting ART? Melanie A. Thompson, MD AIDS Research Consortium of Atlanta Follow me on Twitter @ drmt Financial Relationships With Commercial Entities Dr Thompson's institution has received grants for research from Bristol-Myers Squibb, CytoDyn, Inc, Frontier Biotechnologies, Gilead Sciences, Inc, GlaxoSmithKline, These companies may only pick up pre-arranged customersTAXI COMPANYPHONE NUMBERA-Cab Inc5099981774Advanced Transportation Taxi5092181354Anderson Taxi5092304917Anywhere Transportation5099985610Arrow C Every 2 Months for HIV Maintenance. . ATLAS-2M. IM Cabotegravir and IM . Rilpivirine. Every 2 Months for HIV Maintenance. ATLAS-2M Study. : Design. Source: Overton ET, et al. Lancet. 2020:396:1994-2005.. S. VIDARD . (EDF / SEPTEN. ) - N. JARDIN . (EDF / UNIE. ) - A.M. DONORE . (EDF / R&D. ). 4. th. . PLiM. . conference. Lyon, . october. 2017. Summary. EDF 3-loop RPV life management beyond 40 years of operation . Study GS-366-1216. Switch from TDF to TAF, each with RPV and FTC. Study GS-366-1216: Design. Source: . Orkin. C et al. Lancet HIV. 2017;4:e195-e204.. *. NOTE. :. of 632 participants randomized, 2 were never treated (630 individuals treated). Presented by Carol Nati MD, MS, DFAPA. Medical Director, MHMR of Tarrant County. Overview. Long Acting Injectable Antipsychotic Medications are underutilized in Texas.. They have been proven to work well.. Madeline Droney, PharmD. In it for the Long-Haul. Long-Acting Injectables in HIV Treatment. Conflict of Interest. The presenters report no conflict of interest. Review the treatment recommendations for human immunodeficiency virus (HIV) infection. Extended Release Injectable Suspension. Last Updated: October 6, 2023. Prepared by:. David H. Spach, MD. Brian R. Wood, MD. Cabotegravir and . Rilpivirine. Oral and Injectable Preparations. Source: Cabotegravir-. 2. C Brinson,. 3. F Castelli,. 4. P-M Girard,. 5. LP Kahl,. 6. . E Blair,. 7. B Wynne,. 8. K Vandermeulen,. 9. M Aboud. 10. . SWORD 1 & 2: Switch to . DTG + RPV Maintains Virologic . Suppression Through 48 Weeks, a Phase III Study.